en.Wedoany.com Reported - A study set to be presented at ENDO 2026, the annual meeting of the Endocrine Society in Chicago, Illinois, USA, indicates that among patients with type 2 diabetes, those taking semaglutide have a 15% lower risk of fractures and achieve greater weight loss compared to those using other anti-obesity medications. The research team noted that these results highlight the potential bone-protective effects of semaglutide but recommended prospective studies for further confirmation.
Semaglutide belongs to the class of glucagon-like peptide-1 receptor agonists (GLP-1s), used to treat type 2 diabetes and obesity. Previous studies have suggested that rapid weight loss through GLP-1 drugs may lead to bone thinning and fractures, while more moderate, gradual weight loss could help maintain bone mass. Scientists at Stanford University observed that semaglutide is more effective for weight loss than earlier generations of anti-obesity drugs, but evidence comparing its effects on bone health with other medications is lacking.
Dr. Jairo Noreña, a former endocrinology researcher at Stanford University Medical Center in Palo Alto, California, and colleagues analyzed patients with type 2 diabetes who were taking semaglutide, dulaglutide, or other oral weight-loss medications such as phentermine/topiramate and bupropion/naltrexone, assessing changes in body mass index (BMI) and fracture incidence. The research team conducted a retrospective cohort analysis using the Atropos Health Eos electronic health record dataset, which covers 161 million patients treated at community hospitals and academic medical centers in the United States from January 2016 to December 2023. Participants were adults aged 18 and older with a confirmed diagnosis of type 2 diabetes and no history of prior fractures or use of osteoporosis medications. The intervention group received semaglutide treatment (n=26,324), while the control group received dulaglutide, phentermine/topiramate, or bupropion/naltrexone, with no history of semaglutide use (n=33,555).
Data showed that patients in the semaglutide treatment group experienced greater reductions in BMI compared to the control group. Additionally, the semaglutide group had 794 fracture cases, lower than the 1,045 cases in the control group. Noreña stated that this work provides important early evidence for understanding the impact of semaglutide-induced weight loss on bone health in patients with type 2 diabetes and expressed hope that the study will encourage enhanced monitoring of bone health in weight loss programs.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
